Khalil had no disclosures and no external study funding was noted. One co-investigator reported stock options in Allurion, ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Sales of blood cancer drug Revlimid, which is now facing generic competition, dropped 11% to $1.41 billion in the quarter, ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.32 which represents a decrease of $-1.45 or -2.60% from the prior close of $55.77. The stock opened at $55.88 and ...

Bristol-Myers Squibb Co. (NYSE: BMY) is an American multinational pharmaceutical company that discovers, develops, and ...

In a welcome move, Bristol Myers Squibb saw its Relative Strength Rating improve from 70 to 76 on Tuesday. Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...